Reo Therapeutics Secures £170k in Early-Stage Funding

Reo Therapeutics Limited, a London-based biotechnology firm, has successfully raised £170k in a recent funding round. The capital infusion, with an allotment date of 25 March 2026 and filing on 23 April 2026, marks an early investment into the company's ambitious research and development initiatives.

Incorporated on 3 August 2024, Reo Therapeutics is dedicated to advancing biotechnology through extensive research and experimental development. The company's focus areas include biology research, bioinformatics, cell and tissue culture and engineering, DNA/RNA, gene and RNA vectors, nanobiotechnology, process biotechnology techniques, and proteins and other molecules. By engaging in these diverse activities, Reo Therapeutics aims to contribute to the foundational knowledge and practical applications within the rapidly evolving biotech landscape. Specific financial metrics such as revenue, employee count, or profit/loss figures for the nascent company are not publicly available at this stage.

This £170k funding round represents an initial capital injection for Reo Therapeutics. Details regarding a specific valuation for this round have not been disclosed. As a newly incorporated entity, this is the company's first reported funding round, thus there are no previous rounds for comparison.

In terms of leadership, Andrew John Mcglashan Richards was appointed as a director on 27 March 2026, joining the company's board as it embarks on its growth trajectory.

The funding round for Reo Therapeutics takes place within a dynamic, albeit challenging, UK biotechnology funding landscape. In 2025, the UK biotech sector secured £1.9 billion in equity financing, with venture capital contributing £1.8 billion. This represented a 13.2% decrease in venture capital year-on-year and a 49% decline in total equity financing compared to 2024. Deal volume also saw a significant reduction, falling by 47.7% from 111 deals in 2024.

Investment in 2025 became increasingly concentrated in a small number of large rounds. Early-stage deals, specifically those of £5 million or less, constituted 47% of total transactions but accounted for only 3% of the total capital raised, a decrease from 8% in 2024. Seed rounds, like that secured by Reo Therapeutics, made up 28% of all deals but captured just 5.6% of the total capital in 2025, down from 8% in 2024. This trend highlights a weakening in the capital contribution of early-stage rounds despite their continued prevalence in deal flow.

Despite these challenges, the UK maintained its position as Europe's leading national biotech market in 2025, attracting 30% of all European venture financing. The final quarter of 2025 showed signs of renewed momentum, with 22 completed deals, marking the highest quarterly deal count of the year and indicating a positive shift in investor sentiment heading into 2026. Early data for 2026 suggests "more flow and optimism" in the sector.

While London remains a key hub, over 50% of all life sciences deals and 51% of Seed rounds are now funded outside the capital, with strong regional clusters emerging. However, London continues to offer founder-friendly terms. The broader UK life sciences sector faces ongoing challenges, including a decline in investment growth, reduced pharmaceutical R&D spending, and a drop in foreign direct investment. Nevertheless, opportunities exist through increased mergers and acquisitions activity, potential government co-investment, and reforms aimed at attracting growth capital to London's listing rules. This early funding for Reo Therapeutics underscores continued investor interest in foundational biotechnology research, even within a selective funding environment.